Comparative Pharmacology
Head-to-head clinical analysis: NEO CORT DOME versus NEO MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO CORT DOME versus NEO MEDROL.
NEO-CORT-DOME vs NEO-MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Hydrocortisone is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to glucocorticoid receptors and modulating gene expression.
Neo-Medrol is a combination of neomycin (an aminoglycoside antibiotic) and methylprednisolone (a corticosteroid). Neomycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, while methylprednisolone suppresses inflammation by binding to glucocorticoid receptors, modulating gene expression, and inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Apply topically to affected area twice daily.
Initial dose: 4-48 mg orally per day, divided into 1-4 doses, depending on severity. Intravenous or intramuscular: 10-500 mg/day as methylprednisolone sodium succinate, given as single or divided doses. Intra-articular or soft tissue injection: 4-80 mg as methylprednisolone acetate, depending on joint size.
None Documented
None Documented
2–3 hours (terminal elimination half-life of hydrocortisone); clinically, duration of action is longer due to intracellular receptor binding.
Plasma terminal half-life: 2-4 hours (methylprednisolone); clinical effect half-life ~18-36 hours due to receptor occupancy.
Renal excretion of hydrocortisone metabolites (primarily conjugated as glucuronides and sulfates) accounts for >90% of elimination; <5% biliary/fecal.
Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal excretion minimal.
Category C
Category C
Corticosteroid with Antibiotic
Corticosteroid with Antibiotic